Insights

Market Expansion NecstGen's strategic collaborations with industry leaders like Galapagos NV, Pancancer T, and the Center for Gene and Cellular Therapy at Aarhus University Hospital highlight its active efforts to expand its partnership network. This presents sales opportunities to offer tailored contract manufacturing services, process development, and regulatory support to these partners as they scale their cell and gene therapies.

Service Flexibility With a comprehensive suite of manufacturing and QC services, including GMP rental and process optimization for a wide range of cell and viral vector therapies, NecstGen is well-positioned to attract clients seeking flexible, scalable manufacturing solutions, especially startups and research organizations transitioning into clinical phases.

Innovation Focus NecstGen's recent involvement in cutting-edge therapies such as CAR-T, NK cells, and iPSCs, coupled with its automation and process scale-up capabilities, signals opportunities to sell advanced technological solutions and process development services to biotech firms developing next-generation cell therapies.

Upcoming Leadership The appointment of a new CEO, Rick Hibbert, starting October 2025, indicates potential for strategic growth initiatives and expansion into new markets. This evolution in leadership could be leveraged to pitch innovative collaborations and to align sales efforts with NecstGen's future roadmap.

Funding & Revenue NecstGen's current revenue, estimated between 1 million to 10 million dollars, combined with its active project pipeline and recent partnerships, suggests significant growth potential. Sales teams can target emerging biotech and pharma companies looking for reliable CDMO partnerships to support their clinical and commercial manufacturing needs.

NecstGen Tech Stack

NecstGen uses 8 technology products and services including Cloudflare, WordPress, MySQL, and more. Explore NecstGen's tech stack below.

  • Cloudflare
    Content Management System
  • WordPress
    Content Management System
  • MySQL
    Database
  • Microsoft 365
    Email
  • JSON-LD
    Javascript Frameworks
  • Element UI
    Javascript Frameworks
  • Cloudflare Bot Management
    Security
  • Animate.css
    UI Frameworks

Media & News

NecstGen's Email Address Formats

NecstGen uses at least 1 format(s):
NecstGen Email FormatsExamplePercentage
F.Last@necstgen.comJ.Doe@necstgen.com
91%
First.Last@necstgen.comJohn.Doe@necstgen.com
7%
First@necstgen.comJohn@necstgen.com
2%

Frequently Asked Questions

Where is NecstGen's headquarters located?

Minus sign iconPlus sign icon
NecstGen's main headquarters is located at 62 Sylviusweg Leiden, South Holland 2333 be Netherlands. The company has employees across 1 continents, including Europe.

What is NecstGen's official website and social media links?

Minus sign iconPlus sign icon
NecstGen's official website is necstgen.com and has social profiles on LinkedIn.

What is NecstGen's NAICS code?

Minus sign iconPlus sign icon
NecstGen's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does NecstGen have currently?

Minus sign iconPlus sign icon
As of April 2026, NecstGen has approximately 52 employees across 1 continents, including Europe. Key team members include Chief Financial Officer: J. R.Head Of Business Development & Marketing: T. P.Head Of Viral Vectors: K. N.. Explore NecstGen's employee directory with LeadIQ.

What industry does NecstGen belong to?

Minus sign iconPlus sign icon
NecstGen operates in the Pharmaceutical Manufacturing industry.

What technology does NecstGen use?

Minus sign iconPlus sign icon
NecstGen's tech stack includes CloudflareWordPressMySQLMicrosoft 365JSON-LDElement UICloudflare Bot ManagementAnimate.css.

What is NecstGen's email format?

Minus sign iconPlus sign icon
NecstGen's email format typically follows the pattern of F.Last@necstgen.com. Find more NecstGen email formats with LeadIQ.

When was NecstGen founded?

Minus sign iconPlus sign icon
NecstGen was founded in 2020.

NecstGen

Pharmaceutical ManufacturingSouth Holland, Netherlands51-200 Employees

The Netherlands Center for the Clinical advancement of Cell and Gene Therapies (NecstGen), situated in Leiden, comprises of a state-of-the-art facility and expert knowledge for the development, production, and commercialization of Cell and Gene Therapies. NecstGen helps academic and industrial Cell & Gene Therapy developers to enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC and regulatory affairs in a brand new 4,000 m2 development & GMP manufacturing facility. 

We enable the next generation of therapies by translating research programs into actionalbe health solutions for patients.

Our service offering:

A flexible Cell and Gene Therapy manufacturing model
- Full contract manufacturing services by our expert team for Cell Therapy and Viral Vector
- We manufacture Pre-clinical or toxicology study material, Phase I, Phase II clinical trial material
- GMP rental for any mammalian cell-based therapy type, including Cell and Viral Vector based therapies
- QC, QA, and QP services supporting our cleanroom rental
- Hybrid support on a flexible basis where our team compliments yours

Process and assay development for Cell Therapies and Viral Vector
- Process design and optimisation
- Scale-up to clinically relevant volumes
- Automation and closed processes
- Assay development for in-process controls, release- and potency tests
- Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing
- Consultancy-based work to advise on decision making

Talk to NecstGen today about your needs for:
- Induced Pluripotent Stem Cells (iPSC)
- Chimeric Antigen Receptor T-Cells (CAR-T), Tumor Infiltrating Lymphocytes (TIL) T-Cell Receptor Modified T-Cells (TCR-T)
- Natural Killer (NK) Cells/CAR-NK Cells
- Dendritic Cells (DC)
- Mesenchymal Stromal Cells (MSC)
- Lentivirus (LV)
- Aden-associated virus (AAV)
- Oncolytic viruses
- Cleanroom rental for any mammalian cell-based therapy type

Section iconCompany Overview

Headquarters
62 Sylviusweg Leiden, South Holland 2333 be Netherlands
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2020
Employees
51-200

Section iconFunding & Financials

  • $1M

    NecstGen's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    NecstGen's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.